LIVIVO - Search results -

Search results

Result 1 - 10 of total 175

Search options

Book ; Conference proceedings: New onset diabetes after transplantation

Davidson, Jaime A.

2003 international consensus guidelines ; proceedings of an international expert panel meeting, Barcelona, Spain, 19 February 2003

(Transplantation ; 75,10, Suppl.)

2003

Title variant	New-onset diabetes after transplantation
Author's details	chairmen: Jaime Davidson
Series title	Transplantation ; 75,10, Suppl.
Collection
Language	English
Size	SS24 S. : graph. Darst.
Publisher	Lippincott Williams & Wilkins
Publishing place	Hagerstown, MD
Publishing country	United States
Document type	Book ; Conference proceedings
HBZ-ID	HT013719576
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 488 -75,10,Suppl.-	not available for loan	Zeitschriften-Lesesaal

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.

Davidson, Jaime A

Postgraduate medicine

2019 Volume 131, Issue 4, Page(s) 251–260

Abstract: Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes mellitus (T2DM) and is associated with poor clinical outcomes, including an increased risk of all-cause and cardiovascular mortality, as well as adverse economic and social ... ...

Abstract	Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes mellitus (T2DM) and is associated with poor clinical outcomes, including an increased risk of all-cause and cardiovascular mortality, as well as adverse economic and social effects. Slowing the development and progression of CKD remains an unmet clinical need in patients with T2DM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are widely used for the management of T2DM and have effects beyond glucose lowering that include cardiovascular benefits and potential renoprotective effects. Although the glucose-lowering efficacy of these agents is dependent on renal function, the cardiovascular and renal benefits of SGLT2 inhibition appear to be maintained to estimated glomerular filtration levels as low as 30 mL/min/1.73 m
MeSH term(s)	Albuminuria/metabolism ; Blood Glucose ; Blood Pressure ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2/drug therapy ; Diabetic Cardiomyopathies/prevention & control ; Diabetic Nephropathies/prevention & control ; Glomerular Filtration Rate ; Glycated Hemoglobin A ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors/administration & dosage ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
Chemical Substances	Blood Glucose ; Glycated Hemoglobin A ; Hypoglycemic Agents ; Sodium-Glucose Transporter 2 Inhibitors
Language	English
Publishing date	2019-04-14
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	410138-8
ISSN	1941-9260 ; 0032-5481
ISSN (online)	1941-9260
ISSN	0032-5481
DOI	10.1080/00325481.2019.1601404
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.407: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Conference proceedings: Symposium on Optimization of Insulin Therapy in Diabetes

Davidson, Jaime A.

[circa 2000]

2000

Institution	Symposium on Optimization of Insulin Therapy in Diabetes
Author's details	Symposium contributors: Jaime A. Davidson
Language	English
Publishing country	United States
Document type	Book ; Conference proceedings
Note	In: Endocrine practice. 6 (2000),1, S. 85 - 100
HBZ-ID	HT011237223
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 5034 -6-	not available for loan	Zeitschriften-Lesesaal

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comment on Riddle et al.

Hall, Laura Lee / Puckrein, Gary A / Davidson, Jaime A

Diabetes care

2019 Volume 42, Issue 11, Page(s) e183

MeSH term(s)	Big Data ; Diabetes Mellitus, Type 2 ; Humans ; Hyperglycemia
Language	English
Publishing date	2019-09-19
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	441231-x
ISSN	1935-5548 ; 0149-5992
ISSN (online)	1935-5548
ISSN	0149-5992
DOI	10.2337/dc19-1262
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1434: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 365: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.

Davidson, Jaime A

Postgraduate medicine

2015 Volume 127, Issue 8, Page(s) 827–841

Abstract: In type 2 diabetes mellitus (T2DM), decreased pancreatic beta-cell function and increased insulin resistance contribute to a steady decline in glucose homeostasis. Maintaining levels of glycated hemoglobin ≤7.0% is thought to reduce the microvascular and ...

Abstract	In type 2 diabetes mellitus (T2DM), decreased pancreatic beta-cell function and increased insulin resistance contribute to a steady decline in glucose homeostasis. Maintaining levels of glycated hemoglobin ≤7.0% is thought to reduce the microvascular and possibly macrovascular complications that result if T2DM is not properly managed. Recent guidelines have recognized the importance of postprandial glucose (PPG) control in reducing cardiovascular risks, and have recommended a more patient-centered approach. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) mimic the action of the endogenous gastrointestinal hormone GLP-1 to activate the insulin response in pancreatic beta cells in a glucose-dependent manner. Prandial GLP-1 RAs have a short plasma half-life and are particularly effective at targeting PPG elevations, whereas long-acting non-prandial GLP-1 RAs are more effective at reducing fasting plasma glucose. These differences highlight the potential for treatment with these agents to be tailored to the need of individual patients and their glycemic imbalance. All GLP-1 RAs are being evaluated in long-term cardiovascular outcome trials. To date, the only cardiovascular trial that has been completed is the ELIXA trial for lixisenatide, which was found to meet the pre-specified criterion of non-inferiority versus placebo in terms of cardiovascular outcomes.
MeSH term(s)	Blood Glucose/drug effects ; Delayed-Action Preparations ; Diabetes Mellitus, Type 2/drug therapy ; Drug Therapy, Combination ; Gastric Emptying/drug effects ; Glucagon/secretion ; Glucagon-Like Peptide-1 Receptor/agonists ; Glycated Hemoglobin A/drug effects ; Half-Life ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/pharmacokinetics ; Hypoglycemic Agents/therapeutic use ; Postprandial Period/physiology ; Randomized Controlled Trials as Topic
Chemical Substances	Blood Glucose ; Delayed-Action Preparations ; Glucagon-Like Peptide-1 Receptor ; Glycated Hemoglobin A ; Hypoglycemic Agents ; Glucagon (9007-92-5)
Language	English
Publishing date	2015
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	410138-8
ISSN	1941-9260 ; 0032-5481
ISSN (online)	1941-9260
ISSN	0032-5481
DOI	10.1080/00325481.2015.1096743
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.407: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.

Davidson, Jaime A / Sukor, Norlela / Hew, Fen-Lee / Mohamed, Mafauzy / Hussein, Zanariah

Journal of diabetes investigation

2022 Volume 14, Issue 2, Page(s) 167–182

Abstract: The prevalence of type 2 diabetes mellitus continues to increase in many Asian countries, with possible contributing factors, such as younger-onset disease, diabetes development at lower body mass index, higher visceral fat accumulation and poorer β-cell ...

Abstract	The prevalence of type 2 diabetes mellitus continues to increase in many Asian countries, with possible contributing factors, such as younger-onset disease, diabetes development at lower body mass index, higher visceral fat accumulation and poorer β-cell function, among Asian populations. Sodium-glucose cotransporter 2 inhibitors have been shown to confer favorable effects in type 2 diabetes mellitus patients, such as improved glycemic control, weight and blood pressure reduction, and importantly, cardiorenal benefits. Sodium-glucose cotransporter 2 inhibitors are generally well-tolerated, and have a well-defined safety profile based on evidence from numerous clinical trials and post-marketing pharmacovigilance reporting. To our knowledge, this review is the first to provide a comprehensive coverage of the adverse events of sodium-glucose cotransporter 2 inhibitors, as well as their management and counseling aspects for Asian type 2 diabetes mellitus populations.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2 ; Hypoglycemic Agents/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Glucosides/therapeutic use ; Blood Glucose ; Sodium
Chemical Substances	Hypoglycemic Agents ; Sodium-Glucose Transporter 2 Inhibitors ; Glucosides ; Blood Glucose ; Sodium (9NEZ333N27)
Language	English
Publishing date	2022-10-19
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	2625840-7
ISSN	2040-1124 ; 2040-1116
ISSN (online)	2040-1124
ISSN	2040-1116
DOI	10.1111/jdi.13915
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6920: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Incretin-based therapies: focus on effects beyond glycemic control alone.

Davidson, Jaime A

Diabetes therapy : research, treatment and education of diabetes and related disorders

2013 Volume 4, Issue 2, Page(s) 221–238

Abstract: Type 2 diabetes is associated with a high prevalence of comorbidities resulting from hypertension, dyslipidemia, and hyperglycemia. Inadequate management of these risk factors will eventually result in detrimental health consequences. Thus, the effect of ...

Abstract	Type 2 diabetes is associated with a high prevalence of comorbidities resulting from hypertension, dyslipidemia, and hyperglycemia. Inadequate management of these risk factors will eventually result in detrimental health consequences. Thus, the effect of a drug on factors such as weight, cardiovascular (CV) risk factors, and adherence is important to consider. A review was undertaken of the recent medical literature describing the extraglycemic characteristics of the two classes of incretin-based therapies-glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors. PubMed searches were performed to identify published data on incretin therapies that describe their effects on CV risk factors, CV events, and factors related to medication adherence. The maintenance or loss of weight associated with the use of GLP-1RAs and DPP-4 inhibitors is well described in the medical literature. These agents also appear to be associated with a modest decrease in blood pressure and a reduced risk of CV events. In addition, several characteristics of incretin therapies may improve rates of medication adherence, such as generally favorable tolerability profiles (particularly with DPP-4 inhibitors), the availability of formulations that simplify treatment regimens, and a low risk for hypoglycemia. The literature on incretin therapies describes a number of clinical characteristics that are relevant to the management of extraglycemic risk factors. As part of a holistic treatment strategy, these properties constitute important considerations for tailoring therapy to individual patients with type 2 diabetes.
Language	English
Publishing date	2013-09-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	2566702-6
ISSN	1869-6961 ; 1869-6953
ISSN (online)	1869-6961
ISSN	1869-6953
DOI	10.1007/s13300-013-0040-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies.

Davidson, Jaime A

Journal of managed care pharmacy : JMCP

2013 Volume 20, Issue 2, Page(s) 120–129

Abstract: Background: Oral antihyperglycemic drugs used to treat type 2 diabetes mellitus (T2DM) vary in safety and tolerability. Treatment-related hypoglycemia and weight gain can exacerbate underlying disease. : Objective: To evaluate the tolerability of ... ...

Abstract	Background: Oral antihyperglycemic drugs used to treat type 2 diabetes mellitus (T2DM) vary in safety and tolerability. Treatment-related hypoglycemia and weight gain can exacerbate underlying disease. Objective: To evaluate the tolerability of saxagliptin using data from phase III clinical trials. Methods: Six 24-week randomized studies in 4,214 patients with T2DM were assessed. Saxagliptin 2.5 mg or 5 mg was compared with placebo in 2 trials of monotherapy in treatment-naïve patients and in 3 trials of add-on therapy to metformin, glyburide, or a thiazolidinedione; initial combination therapy with saxagliptin 5 mg plus metformin was compared with metformin monotherapy in treatment-naïve patients. Data from the monotherapy and add-on studies were pooled; data from the initial combination study were analyzed separately. No statistical analyses of between-group comparisons across studies were conducted for these safety analyses because of multiplicity of end points and relative lack of statistical power and because small differences not reaching statistical significance have the potential to be clinically relevant. Results: In the pooled analysis, incidence rates for adverse events (AEs) with saxagliptin 2.5 mg, 5 mg, and placebo were 72.0% (635/882), 72.2% (637/882), and 70.6% (564/799), respectively; rates for serious AEs (SAEs) were 3.5% (31/882), 3.4% (30/882), and 3.4% (27/799); rates of discontinuation due to AEs were 2.2% (19/882), 3.3% (29/882), and 1.8% (14/799). AEs reported in ≥ 2% of patients receiving saxagliptin and occurring ≥ 1% more frequently with saxagliptin than with placebo were sinusitis, gastroenteritis, abdominal pain, and vomiting. In the initial combination study, AE incidence rates with saxagliptin 5 mg plus metformin and metformin monotherapy were 55.3% (177/320) and 58.5% (192/328), respectively; incidence rates for SAEs were 2.5% (8/320) and 2.4% (8/328); and rates of discontinuation due to AEs were 2.5% (8/320) and 3.4% (11/328). Conclusion: Saxagliptin 2.5 mg or 5 mg was generally well tolerated as monotherapy, add-on combination therapy with other oral antihyperglycemic drugs, and initial combination with metformin.
MeSH term(s)	Adamantane/administration & dosage ; Adamantane/adverse effects ; Adamantane/analogs & derivatives ; Adamantane/pharmacology ; Clinical Trials, Phase III as Topic ; Diabetes Mellitus, Type 2/drug therapy ; Dipeptides/administration & dosage ; Dipeptides/adverse effects ; Dipeptides/pharmacology ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Humans ; Hypoglycemia/chemically induced ; Hypoglycemia/epidemiology ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
Chemical Substances	Dipeptides ; Hypoglycemic Agents ; saxagliptin (9GB927LAJW) ; Adamantane (PJY633525U)
Language	English
Publishing date	2013-05-17
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2022394-8
ISSN	1944-706X ; 1083-4087
ISSN (online)	1944-706X
ISSN	1083-4087
DOI	10.18553/jmcp.2014.20.2.120
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5450: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Diabetes and Medicare competitive bidding: the "perfect storm" for patient harm.

Davidson, Jaime A / Parkin, Christopher

The American journal of managed care

2016 Volume 22, Issue 7 Spec No., Page(s) SP252–SP253

Abstract: A recent Diabetes Care study found flaws in Medicare's competitive bidding program for diabetes test strips. Two of that study's co-authors discuss the findings and why CMS should suspend the bidding program. ...

Abstract	A recent Diabetes Care study found flaws in Medicare's competitive bidding program for diabetes test strips. Two of that study's co-authors discuss the findings and why CMS should suspend the bidding program.
Language	English
Publishing date	2016-05
Publishing country	United States
Document type	Journal Article
ZDB-ID	2035781-3
ISSN	1936-2692 ; 1088-0224 ; 1096-1860
ISSN (online)	1936-2692
ISSN	1088-0224 ; 1096-1860
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5353: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 86: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The status of diabetes and its complications in Latin-American population: A review article.

Correa, Ricardo / Harsha Tella, Sri / Elshimy, Ghada / Davidson, Jaime A

Diabetes research and clinical practice

2020 Volume 168, Page(s) 108274

Abstract: The Latino population consists of distinct cultural groups, with differences in dietary habits and lifestyle that can affect the risk for type 2 diabetes. The best terminology today is Latino/Hispanic, and it should only be used as ethnicity. Latin- ... ...

Abstract	The Latino population consists of distinct cultural groups, with differences in dietary habits and lifestyle that can affect the risk for type 2 diabetes. The best terminology today is Latino/Hispanic, and it should only be used as ethnicity. Latin-America has different races such as Caucasians, Native Americans, Blacks and Asians, and many mixtures of all. The leading cause of death in Latin-America is Cardiovascular diseases and the most important risk factor is diabetes mellitus (DM). According to the latest estimates from the Global Burden of Disease, the burden of DM was greater than expected in Latin America and the Caribbean region. Extensive data illustrates that lower cardiovascular disease risk in Latino group is a paradox. Instead, it is evident that the cardiovascular disease is the leading cause of mortality in Latinos.
MeSH term(s)	Diabetes Mellitus, Type 2/complications ; Female ; Humans ; Latin America/epidemiology ; Male ; Risk Factors
Language	English
Publishing date	2020-06-18
Publishing country	Ireland
Document type	Journal Article ; Review
ZDB-ID	632523-3
ISSN	1872-8227 ; 0168-8227
ISSN (online)	1872-8227
ISSN	0168-8227
DOI	10.1016/j.diabres.2020.108274
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2047: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito